Although the tested BTK inhibitors are, at best, equally efficient as teriflunomide in suppressing relapses in relapsing/MRI-active MS study participants, these observations consistently show that tolebrutinib does delay confirmed progression of disability compared to teriflunomide in relapsing/MRI-active MS and compared to placebo in non-relapsing MS. This evidence concerns the gene BTK and myeloid sarcoma.